The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Open accessAbstract
Neurotoxic amyloid beta peptide (Abeta) accumulates in the brains of individuals with Alzheimer disease (AD). The APOE4 allele is a major risk factor for sporadic AD and has been associated with increased brain parenchymal and vascular amyloid burden. How apoE isoforms influence Abeta accumulation in the brain has, however, remained unclear. Here, we have shown that apoE disrupts Abeta clearance across the mouse blood-brain barrier (BBB) in an isoform-specific manner (specifically, apoE4 had a greater disruptive effect than either apoE3 or apoE2). Abeta binding to apoE4 redirected the rapid clearance of free Abeta40/42 from the LDL receptor-related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and Abeta-apoE4 complexes at the BBB more slowly than LRP1. In contrast, apoE2 and apoE3 as well as Abeta-apoE2 and Abeta-apoE3 complexes were cleared at the BBB via both VLDLR and LRP1 at a substantially faster rate than Abeta-apoE4 complexes. Astrocyte-secreted lipo-apoE2, lipo-apoE3, and lipo-apoE4 as well as their complexes with Abeta were cleared at the BBB by mechanisms similar to those of their respective lipid-poor isoforms but at 2- to 3-fold slower rates. Thus, apoE isoforms differentially regulate Abeta clearance from the brain, and this might contribute to the effects of APOE genotype on the disease process in both individuals with AD and animal models of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using homozygous human APOE knock-in mice, previous work demonstrated that APOE4 promotes A β aggregation and impairs its clearance relative to APOE3 34,38,39 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE exerts toxic effects on the cerebrovascular system (694) and neurons (383, 384) and influences A 𝛃 clearance (60, 64, 98, 135, 256, 266, 278, 294, 315, 693), amyloid deposition (39, 256, 258, 266, 278, 314, 518, 612), and tau-related neurodegeneration (533) in an allele-dependent manner APOE4 > APOE3 > APOE2 .”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact increased rate of soluble Aβ clearance across the BBB has been experimentally confirmed in the setting of the APOE ε2 allele [32, 48].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, the contribution of ISF bulk flow to total Aβ clearance was minimal (Fig. 1B), consistent with previous studies (14, 15, 20).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When injecting low nM [ 125 I] Aβ 1-42 concentrations in mice, we found no significant amount of radioactivity in the CSF, showing that the small amounts of injected Aβ are rapidly cleared via the BBB and that a minor amount of injected Aβ is cleared via bulk flow as also observed by previous studies (8,11,12).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LRP1 also binds APOE2 and APOE3 as well as APOE2-A 𝛃 and APOE3-A 𝛃 complexes at the abluminal side of the BBB, mediating their efflux from brain-toblood (135).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in animal models support that APOE4 compared with APOE3 and APOE2 diminishes A 𝛃 clearance across the BBB (58, 135), which has been confirmed in transgenic APOE4 mice (98).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“and in animal models, APOE4 compared with APOE3 and APOE2 leads to impaired clearance of A 𝛃 across the BBB (58, 98, 135) and an early BBB breakdown and transporters' dysregulation (9, 60, 85, 437).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study wherein apoE/Aβ complexes were microinjected into wildtype mouse brain revealed that Aβ bound to apoE4 is cleared more slowly than when Aβ is complexed to apoE3 or apoE2 (56).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies demonstrated that apoE isoforms can differentially affect Aβ clearance (Deane et al., 2008; Jiang et al., 2008; Castellano et al., 2011).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, recent studies strongly suggest that apoE regulates both extracellular and intracellular Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, apoE has been shown to regulate Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ complexed to apoE2 and apoE3 is cleared out of the brain at a significantly faster rate than Aβ complexed to apoE4 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“A recent study has shown that the brain to blood clearance of lipidated apoE4 in the mouse brain is significantly lower than the clearance of apoE3 and apoE2 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Accumulating recent evidence strongly suggests that when human apoE is complexed with Aβ, the brain to blood clearance of Aβ is actually decreased compared to that of free Aβ (Bell et al., 2007; Deane et al., 2008; Ito et al., 2007).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“In animal models, Aβ–ApoE2 and Aβ–ApoE3 complexes are cleared by the blood brain barrier (BBB) at a substantially higher rate than Aβ–ApoE4 complexes [23].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“These results suggest the LDLR overexpression in neurons and astrocytes (18) likely increases BBB-mediated Aβ clearance through an indirect mechanism involving other apoE receptors at the BBB, such as LRP1—a receptor shown to directly mediate Aβ clearance across the BBB (14, 15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“our work strongly suggests that LDLR influences Aβ metabolism by affecting its clearance from the brain into blood, a mechanism previously suggested only for LRP1 and VLDLR (13–15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Although low-density lipoprotein receptor-related protein 1 (LRP1) has been well characterized for its role in BBB-mediated Aβ clearance (13–15), whether LDLR plays a role in Aβ clearance across the BBB is unclear.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE has been shown to impede the clearance of Aβ from brain ISF (13, 15, 43); therefore, it is likely that the reduction of apoE levels with LDLR overexpression facilitates greater ISF Aβ clearance across the BBB.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies suggest that transport across the BBB is a major elimination route for brain Aβ (8,11,12,15).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationRovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Research works printed but not linked: 2
- Tanzi, 2004, Neuron., 43, 605
- 10.1042/0264-6021:3480359 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 767
The Role of Lipid Bodies in the Microglial Aging Process and Related Diseases
Hu, X., Xu, B., & Ge, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2351-4 · Cited by 17
Stephen, T., Breningstall, B. M., Suresh, S., McGill, C. J., & Pike, C. J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02650-4 · Cited by 17
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 17
Cerebrospinal Fluid Proteins as Regulators of Beta‐amyloid Aggregation and Toxicity
Pate, K. M., & Murphy, R. M. (2017) · Israel Journal of Chemistry · doi:10.1002/ijch.201600078 · Cited by 17
Régy, M., Dugravot, A., Sabia, S., Fayossé, A., Mangin, J., Marie Chupin, A., Fischer, C., Bouteloup, V., Dufouil, C., Chêne, G., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118966 · Cited by 23
Age and apolipoprotein E ε4 effects on neural correlates of odor memory.
Green, A. J., Cervantez, M. R., Graves, L. V., Morgan, C. D., & Murphy, C. A. (2013) · Behavioral Neuroscience · doi:10.1037/a0031891 · Cited by 19
Iurescia, S., Fioretti, D. P., Mangialasche, F., & Rinaldi, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100009 · Cited by 18
The glymphatic system as a therapeutic target: TMS-induced modulation in older adults
Sundman, M., Liu, Y., Chen, N., & Chou, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1597311 · Cited by 17
Association of APOE genotype with blood-brain barrier permeability in neurodegenerative disorders
Libri, I., Silvestri, C., Caratozzolo, S., Alberici, A., Pilotto, A., Archetti, S., Trainini, L., Borroni, B., Padovani, A., & Benussi, A. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.04.003 · Cited by 16
Cerebral amyloid angiopathy and the immune system
Munsterman, D., Falcione, S. R., Long, R., Boghozian, R., Joy, T., Camicioli, R. M., Smith, E. E., & Jickling, G. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13826 · Cited by 16
Fertan, E., Hung, C., Danial, J. S. H., Lam, J. Y. L., Preman, P., Albertini, G., English, E. A., Böken, D., Livesey, F. J., Strooper, B. D., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae454 · Cited by 16
AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes
Rossello, X. S., Igbavboa, U., Weisman, G. A., Sun, G. Y., & Wood, W. G. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.017 · Cited by 16
Liu, Y., Song, J., Xu, W., Hou, X., Li, J., Yu, J., Tan, L., Chi, S., & Initiative, A. A. D. N. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.633576 · Cited by 16
Dilliott, A. A., Sunderland, K. M., McLaughlin, P. M., Roberts, A., Evans, E. C., Abrahão, A., Binns, M. A., Black, S. E., BORRIE, M. J., Casaubon, L. K., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.011 · Cited by 18
Syndapin-2 mediated transcytosis of amyloid-β across the blood–brain barrier
Leite, D. M., Seifi, M., Ruiz‐Pérez, L., Nguemo, F., Plomann, M., Swinny, J. D., & Battaglia, G. (2022) · Brain Communications · doi:10.1093/braincomms/fcac039 · Cited by 16
Scarfò, G., Piccarducci, R., Daniele, S., Franzoni, F., & Martini, C. (2022) · Antioxidants · doi:10.3390/antiox11112116 · Cited by 16
The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer’s Disease
Benussi, L., Ghidoni, R., Piaz, F. D., Binetti, G. G., Iorio, G. D., & Abrescia, P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160930 · Cited by 16
Disentangling Heterogeneity in Alzheimer’s Disease: Two Empirically-Derived Subtypes
Blanken, A. E., Dutt, S., Li, Y., Nation, D. A., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190230 · Cited by 16
He, K., Li, B., Huang, L., Zhao, J., Hua, F., Wang, T., Li, J., Wang, J., Huang, Q., Chen, K., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10366-z · Cited by 15
Genetic and environmental risk factors for dementia in African adults: A systematic review
Donkor, D. M., Marfo, E., Bockarie, A. S., Tettevi, E. J., Antwi, M. H., Dogah, J., Osei, G. N., & Simpong, D. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70220 · Cited by 15
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 16
Women with the Alzheimer’s risk marker ApoE4 lose Aβ-specific CD4+ T cells 10–20 years before men
Begum, A. N., Cunha, C. D., Sidhu, H., Alkam, T., Scolnick, J., Rosario, E. R., & Ethell, D. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.51 · Cited by 15
Wang, J., Wang, M., Ren, S., Huang, L., He, K., Li, J., Hua, F., Guan, Y., Guo, Q., Huang, Q., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221166 · Cited by 15
Ueno, M. (2017) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001004 · Cited by 15
Brockmann, K., Lerche, S., Dilger, S. S., Stirnkorb, J. G., Apel, A., Hauser, A., Liepelt‐Scarfone, I., Berg, D., Gasser, T., Schulte, C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004705 · Cited by 15
Rodrigues, R., Smith, M. A., Wang, X., Perry, G. L., Lee, H., Zhu, X., & Petersen, R. B. (2012) · Future Neurology · doi:10.2217/fnl.12.27 · Cited by 14
Fu, Y., Zhao, D., Pan, B., Wang, J., Cui, Y., Shi, F., Wang, C., Yin, X., Zhou, X., & Yang, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150312 · Cited by 14
Initiative, T. A. D. N., Pyun, J.-M., Park, Y. H., Kim, H.-R., Suh, J., Kang, M. J., Kim, B. J., Youn, Y. C., Jang, J.-W., & Kim, S. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0326-y · Cited by 14
Jäkel, L., Biemans, E. A. L. M., Klijn, C. J. M., Kuiperij, H. B., & Verbeek, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01873-x · Cited by 15
Wang, Y., Xue, Y., Wang, S., Huang, J., & Yang, X. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03542 · Cited by 14
Romo, E. Z., & Zivkovic, A. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.928566 · Cited by 15
Keller, L., Murphy, C., Wang, H., Fratiglioni, L., Olin, M., Gåfvels, M. E., Björkhem, I., Graff, C., & Meaney, S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.073 · Cited by 14
Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease
Schwab, E. D. P., Queiroz, R., Fiebrantz, A. K. B., Bastos, M., Bonini, J. S., & da Silva, W. C. F. N. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022rw0170 · Cited by 13
The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts
Inoue, K., Tanaka, N., Yamashita, F., Sawano, Y., Asada, T., & Goto, Y. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31014 · Cited by 13
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 13
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 12
Giorgio, J., Jonson, C., Wang, Y., Yokoyama, J. S., Wang, J., Jagust, W. J., & Initiative, O. B. O. T. A. D. N. (2025) · Nature Communications · doi:10.1038/s41467-025-60370-8 · Cited by 14
Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease
Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 12
Nilsson, L. N. G., Gografe, S., Costa, D. A., Hughes, T., Dressler, D., & Potter, H. (2012) · Technology & Innovation · doi:10.3727/194982412x13462021398010 · Cited by 13
Blood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 12
Self-citationGao, L., Jiang, Y., Wei, S., Shang, S., Li, P., Chen, C., Dang, L., Wang, J., Huo, K., Deng, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180399 · Cited by 12
Genetic Biomarkers in Alzheimer’s Disease
Khan, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00004-3 · Cited by 13
Perks, C. M., Barker, R. M., Alhadrami, M., Alkahtani, O., Gill, E., Grishaw, M., Harland, A. J., Henley, P., Li, H., O’Sullivan, E., et al. (2025) · Genes · doi:10.3390/genes16030331 · Cited by 11
Association of LRRTM3 polymorphisms with late-onset Alzheimer's disease in Han Chinese
Wang, J., Yu, J., Jiang, T., Tan, M., Wang, H.-F., Tan, L., Hu, N., Sun, L., Zhang, W., & Tan, L. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.01.013 · Cited by 11
Haferkamp, U., Hartmann, C., Abid, C. L., Brachner, A., Höchner, A., Gerhartl, A., Harwardt, B., Leckzik, S., Leu, J., Metzger, M., et al. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00471-y · Cited by 12
Immune cells in Alzheimer’s disease: insights into pathogenesis and potential therapeutic targets
Fu, X., Cai, H., Quan, S., Ren, Z., Xu, Y., & Jia, L. (2024) · Medical Review · doi:10.1515/mr-2024-0064 · Cited by 10
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 11
P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities
Asante, J., & Barger, S. W. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2495632 · Cited by 11
Regulation of Alzheimer's disease-associated proteins during epileptogenesis
von Rüden, E., Zellinger, C., Gedon, J., Walker, A., Bierling, V., Deeg, C. A., Hauck, S. M., & Potschka, H. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.037 · Cited by 11
Map kinase and PKC signaling pathways modulate NGF-mediated apoE transcription
Strachan-Whaley, M. R., Reilly, K., Dobson, J., & Kalisch, B. E. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.032 · Cited by 12
Washington, P. M., & Burns, M. P. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw049 · Cited by 11
Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain
Majou, D., & Dermenghem, A.-L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148681 · Cited by 10
Pu, Y., Dai, X., Wang, Y., Chen, Y., Wu, C., Zhou, X., Chen, M., Chen, Y., Shuai, X., Jin, R., et al. (2025) · Advanced Materials · doi:10.1002/adma.202418560 · Cited by 11
Xie, G., Jiang, G., Huang, L., Sun, S., Wan, Y., Li, F., Wu, B., Zhang, Y., Li, X., Xiong, B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060790 · Cited by 10
Savignac, C., Villeneuve, S., Badhwar, A., Saltoun, K., Shafighi, K., Zajner, C., Sharma, V., Taliun, S. A. G., Farhan, S. M. K., Poirier, J., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001863 · Cited by 11
Ganesan, K., Rentsch, P., Langdon, A., Milham, L. T., & Vissel, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1357405 · Cited by 11
Advances and Challenges in Gene Therapy for Alzheimer’s Disease
Morroni, F., & Caccamo, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230783 · Cited by 11
Iketani, R., Ohno, K., Kawasaki, Y., Matsumoto, K., Yamada, H., & Kishino, S. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00929 · Cited by 10
Fernandez, F., & Reeves, R. H. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_12 · Cited by 11
Wang, K., & Zhang, W. (2021) · Synapse · doi:10.1002/syn.22196 · Cited by 11
Protein Interactome of Amyloid-β as a Therapeutic Target
Lazarev, V. F., Dutysheva, E. A., Kanunikov, I. E., Guzhova, I. V., & Margulis, B. A. (2023) · Pharmaceuticals · doi:10.3390/ph16020312 · Cited by 9
Ma, X., Li, J., Yang, Y., Qiu, X., Sheng, J., Han, N., Wu, C., Xu, G., Jiang, G., Tian, J., et al. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120762 · Cited by 9
The Blood–Brain Barrier in Neuroinflammation
Shimizu, F., & Kanda, T. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_10 · Cited by 9
Anderson, M. E., Xu, F., Ou-Yang, M.-H., Davis, J., Nostrand, W. E. V., & Robinson, J. K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160674 · Cited by 9
Cerebral Apolipoprotein D Exits the Brain and Accumulates in Peripheral Tissues
Desmarais, F., Hervé, V., Bergeron, K., Ravaut, G., Perrotte, M., Fyfe-Desmarais, G., Rassart, É., Ramassamy, C., & Mounier, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084118 · Cited by 9
Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele
Ji, X., Peng, X., Tang, H., Pan, H., Wang, W. D., Wu, J., Chen, J., & Wei, N. (2023) · Brain Pathology · doi:10.1111/bpa.13208 · Cited by 9
Zhou, M., Fu, X., Ma, B., Chen, Z., Cheng, Y., Liu, L., Kan, S., Zhao, X., Feng, S., Jiang, Z., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1274642 · Cited by 9
Wesén, E. V., Lundmark, R., & Esbjörner, E. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00053 · Cited by 9
Shi, X., Ren, S., Zhang, B., Guo, S., He, W., Yuan, C., Yang, X., Ig-lzevbekhai, K., Sun, T., Wang, Q., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90982-1 · Cited by 9
Asiamah, E. A., Feng, B., Guo, R., Yaxing, X., Du, X., Liu, X., Zhang, J., Cui, H., & Ma, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230658 · Cited by 8
Dasadhikari, S., Ghosh, S., Pal, S., Knowles, T. P. J., & Garai, K. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01524-z · Cited by 9
Yao, Y., Shaligram, S. S., & Su, H. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64034-5.00005-5 · Cited by 8
Kong, F., Wu, T., Dai, J., Cai, J., Zhai, Z., Zhu, Z., Xu, Y., & Sun, T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295008 · Cited by 8
Spinedi, M., Clark, C., Zullo, L., Kerksiek, A., Pistis, G., Castelao, E., von Gunten, A., Preisig, M., Lütjohann, D., & Popp, J. (2024) · iScience · doi:10.1016/j.isci.2024.109013 · Cited by 8
Pharmacokinetic properties of MH84, a γ-secretase modulator with PPARγ agonistic activity
Pellowska, M., Stein, C., Pohland, M., Merk, D., Klein, J., Eckert, G. P., Schubert‐Zsilavecz, M., & Wurglics, M. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.10.001 · Cited by 8
Samy, A. S., & Igwe, O. J. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9670-8 · Cited by 8
Bonnar, O., Shaw, K., Anderle, S., Grijseels, D. M., Clarke, D., Bell, L., King, S. L., & Hall, C. N. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231172842 · Cited by 8
Association of Alzheimer's Disease With APOE and IL-1α Gene Polymorphisms
Yıldız, S. H., Erdoğan, M. Ö., Artan, S., Solak, M., Yaman, M., Ozbabalik, B. D., & Söylemez, E. S. A. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512461557 · Cited by 8
LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice
Stukas, S., Freeman, L., Lee, M., Wilkinson, A., Ossoli, A., Vaisman, B., Demosky, S., Chan, J., Hirsch-Reinshagen, V., Remaley, A. T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049940 · Cited by 9
Lipid metabolism and Alzheimer's disease: pathways and possibilities
Saxena, U. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902738720 · Cited by 9
Looking at Alzheimer’s Disease Pathogenesis from the Nuclear Side
D’Andrea, L., Stringhi, R., Luca, M. D., & Marcello, E. E. (2021) · Biomolecules · doi:10.3390/biom11091261 · Cited by 8
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 8
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?
Higgins, M. J., Wasef, V., & Kwakowsky, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020883 · Cited by 7
Rogojin, A., Gorbet, D. J., Hawkins, K. M., & Sergio, L. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1054523 · Cited by 7
Endothelial Cell APOE3 Regulates Neurovascular, Neuronal, and Behavioral Function
Marottoli, F. M., Zhang, H., Flores-Barrera, E., de la Villarmois, E. A., Damen, F. C., Fernández, A. M. M. M., Blesson, H. V., Chaudhary, R., Nguyen, A. L., Nwokeji, A. E., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319816 · Cited by 7
Ankul Singh, S., Ansari, M. N., Elossaily, G. M., Vellapandian, C., & Prajapati, B. G. (2024) · ACS Omega · doi:10.1021/acsomega.3c06328 · Cited by 7
Xu, Y., Zhang, J., & Li, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1328334 · Cited by 7
Frisardi, V. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111568 · Cited by 7
Role of Apolipoprotein E in the tangled mystery of pain
Dhillon, H., & Singh, S. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.02.033 · Cited by 7
An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer’s Disease
Menta, B. W., & Swerdlow, R. H. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2603-y · Cited by 7
Yamagishi, S., Iga, Y., Ikegaya, S., Kakiuchi, T., Ohba, H., Nishiyama, S., Fukomoto, D., Kanazawa, M., Harada, N., Tsukada, H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02343-4 · Cited by 7
Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease
Li, X., Li, Z., Chen, H., Guo, H., Ge, Y., Dong, F., Zhang, F., & Zhang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115199 · Cited by 7
Azmi, N. H., Ismail, N., Imam, M. U., Ooi, D. J., Zhang, Y., Aziz, A. H. A., & Rosdi, M. N. M. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105587 · Cited by 5
ApoE Isoforms Inhibit Amyloid Aggregation of Proinflammatory Protein S100A9
Ghosh, S., Tamilselvi, S., Williams, C., Jayaweera, S. W., Iashchishyn, I. A., Šulskis, D., Gilthorpe, J. D., Olofsson, A., Smirnovas, V., Svedružić, Ž. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042114 · Cited by 6
Contactin 5 and Apolipoproteins Interplay in Alzheimer’s Disease
Dauar, M. T., Picard, C., Labonté, A., Breitner, J. C. S., Rosa‐Neto, P., Villeneuve, S., & Poirier, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231003 · Cited by 6
Li, W., Wang, X., Sun, L., Yue, L., & Xiao, S. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1417499 · Cited by 7
Bello-Corral, L., Seco‐Calvo, J., Fresno, Á. M., González, A. I., Llorente, A. M., Fernández‐Lázaro, D., & Sánchez-Valdeón, L. (2024) · Medicina · doi:10.3390/medicina60121941 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 6
Hou, H., Habib, A., Zi, D., Tian, K., Tian, J., Giunta, B. N., Sawmiller, D. R., & Tan, J. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8446-x · Cited by 6
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 7
Metadata
- Authors
- Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2008-12-01
- Volume
- 118
- Issue
- 12
- Pages
- 4002-4013
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2582453
- OpenAlex
- W2138992210
- Cited by
- 771
- References
- 71
- Citations by year
- 2026: 35 · 2025: 39 · 2024: 51 · 2023: 40 · 2022: 42 · 2021: 48 · 2020: 47 · 2019: 47 · 2018: 35 · 2017: 49 · 2016: 38 · 2015: 51 · 2014: 48 · 2013: 41 · 2012: 52
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Institutes of Health (R37 NS34467, NS34467, AG13956, R37 AG13956)
- National Institute on Aging (R37AG023084, R37AG13956, R37AG013956)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE isoforms, APOE ε4, Alzheimer's disease, blood-brain barrier, LRP1, VLDLR, APOE2, APOE3, amyloid accumulation
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Blood-Brain Barrier, Disease Models, Animal, Humans, Male, Receptors, LDL, Amyloid beta-Peptides, Protein Isoforms, Tumor Suppressor Proteins, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
